Overall Characteristics of TNBC Patients
| Characteristic | No. of patients (n = 20) |
| Tumor classification | |
| T1 | 0 |
| T2 | 7 (35) |
| T3 | 6 (30) |
| T4 | 7 (35) |
| Lymph node classification | |
| N0 | 7 (35) |
| N1 | 7 (35) |
| N2 | 3 (15) |
| N3 | 3 (15) |
| AJCC clinical stage | |
| IIA | 3 (15) |
| IIB | 6 (30) |
| IIIA | 3 (15) |
| IIIB | 5 (25) |
| IIIC | 3 (15) |
| Tumor type | |
| Invasive ductal, no special type | 18 (90) |
| Metaplastic | 2 (10) |
| Lobular | 0 |
| Grade | |
| 1 | 0 |
| 2 | 5 (25) |
| 3 | 15 (75) |
| Chemotherapy | |
| EC-T | 14 (70) |
| SIM | 6 (30) |
| Surgery | |
| Breast-conserving | 6 (30) |
| Mastectomy | 14 (70) |
| Pathologic response | |
| pCR | 6 (30) |
| Non-pCR | 14 (70) |
Data in parentheses are percentages. Mean age was 51.6 y, and age range was 22–78 y.
AJCC = American Joint Committee on Cancer; EC-T = sequential regimen of 4 cycles of epirubicin (75 mg/m2) plus cyclophosphamide (750 mg/m2), followed by 4 courses of docetaxel (100 mg/m2); SIM = intensified regimen of epirubicin (75 mg/m2) plus cyclophosphamide (1,200 mg/m2) for 6 cycles.